Centro de Química Inorgánica, CEQUINOR (CONICET-UNLP), Bv, 120 1465, La Plata, Argentina.
Curr Treat Options Oncol. 2021 Mar 20;22(5):41. doi: 10.1007/s11864-021-00839-y.
Osteosarcoma (OS), the most common primary malignant bone tumor, is a vastly aggressive disease in children and adolescents. Although dramatic progress in therapeutic strategies have achieved over the past several decades, the outcome remains poor for most patients with metastatic or recurrent OS. Nowadays, conventional treatment for OS patients is surgery combined with multidrug chemotherapy including doxorubicin, methotrexate, and cisplatin (CDDP). In this sense, cisplatin (CDDP) is one of the most drugs used in the treatment of OS but drug resistance to CDDP appears as a serious problem in the use of this drug in the treatment of OS. Thus, we consider that the understanding the molecular mechanisms and the genes involved that lead to CDDP resistance is essential to developing more effective treatments against OS. In this review, we present an outline of the key role of the long non-coding RNAs (lncRNAs) in CDDP resistance in OS. This overview is expected to contribute to understand the mechanisms of CDDP resistance in OS and the relationship of the expression regulation of several lncRNAs.
骨肉瘤（OS）是最常见的原发性恶性骨肿瘤，在儿童和青少年中是一种极具侵袭性的疾病。尽管在过去几十年中治疗策略取得了显著进展，但对于大多数转移性或复发性 OS 患者，其预后仍然较差。目前，OS 患者的常规治疗是手术联合多药化疗，包括阿霉素、甲氨蝶呤和顺铂（CDDP）。从这个意义上说，顺铂（CDDP）是治疗 OS 最常用的药物之一，但 CDDP 耐药性是该药物治疗 OS 中出现的一个严重问题。因此，我们认为，了解导致 CDDP 耐药性的分子机制和相关基因对于开发针对 OS 的更有效治疗方法至关重要。在这篇综述中，我们概述了长链非编码 RNA（lncRNAs）在 OS 中 CDDP 耐药性中的关键作用。这一综述有望有助于理解 OS 中 CDDP 耐药性的机制以及几种 lncRNA 的表达调控关系。
